![](https://investorshub.advfn.com/uimage/uploads/2021/2/24/Aspose.Words.44549174-87bb-4c92-9f97-e726fca5a55c.001.png)
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Develops
Version
3.0
of THC Breath Analyzer Device
Cannabix is developing the Cannabix Marijuana Breathalyzer devices
to give law enforcement and employers a tool to enhance public
safety
Vancouver, British
Columbia -- February
25,
2021 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer of the Cannabix Marijuana Breathalyzer
devices
for law
enforcement and the workplace, is pleased to
report that it has developed
the latest version of the THC Breath Analyzer ("THCBA) prototype
and portable system for field use. The new system incorporates a
new protective case which houses a sterilization module, smart
sample preparation stage and integrated battery charging
system.
In
addition, engineers have enhanced the handheld device for field use
in several ways including revisions to the screen placement,
improved breath flow analysis and upgraded microcontroller. New
images of the THCBA version 3.0 are included in this press release
and available on the Company's website.
![](https://investorshub.advfn.com/uimage/uploads/2021/2/24/Aspose.Words.44549174-87bb-4c92-9f97-e726fca5a55c.002.jpeg)
THCBA testing is
ongoing and is focused on training the device's machine learning
database, determining sensitivity ranges and improving user and
administrator experience. The THCBA has been built to provide easy
to understand screen prompts for the positive and negative
detection of ?9-tetrahydrocannabinol
("THC")
- the psychoactive component of marijuana that causes
impairment in breath, and can be
administered with limited training. The system provides results in
under five minutes.
The THCBA
has been
targeted for employers and other
markets who are seeking a way to quickly, easily and non-invasively
test for recent use of THC.
Employers
everywhere are struggling with the limitations of current drug
testing technology in identifying recent use of marijuana that may
be causing impairment during work hours and differentiating this
from recreational and medical use during nonwork hours/days. The
Cannabix device allows for more relevant THC detection from breath
allowing employers to create an onsite regiment whereby they can
perform pre-access testing for recent use of marijuana before and
during work hours, instead of testing for drug use when employees
are not at work.
Current forms of testing for
marijuana use can identify THC ranging from minutes to days prior
to actual use, making it impossible to show the difference between
the two. Studies¹
have shown that breath is a better indicator of impairment than
saliva, blood, or urine because THC is present in breath for a
relatively short period of time (1-3 hours); whereas, it is
excreted at detectable levels in other body fluids for many hours,
days, or even weeks after smoking. This short time period of
detection in breath aligns with the peak impairment
window.
The Company wants to
acknowledge the rapidly changing
environment for cannabis use in the U.S. The November election in
the U.S. saw the addition of Arizona, Montana, New
Jersey, and South Dakota approving
recreational
marijuana legalization. In
February,
news agencies have
reported
that that top
Democrats including
senators
Cory
Booker (NJ), Ron Wyden (OR), and Chuck Schumer (NY)
are
seeking to advance comprehensive
cannabis reform legislation in the United States
Congress.
These kinds of significant
developments
increase
the focus on public
safety as cannabis use is
legalized in new
jurisdictions
and
emphasizes the
importance of the kinds of tools that
Cannabix Technologies
is
developing to support public
safety.
(1) Olla P,
Ishraque
MT,
Bartol
S. 2020.
Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration
Trends Postcannabis
Exposure
in Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
Himes S.
et al. 2013. Cannabinoids in Exhaled Breath following Controlled
Administration of Smoked Cannabis. Clinical Chemistry;
1780–1789.
Beck
O, Sandqvist
S,
Dubbelboer
I, Franck
J. 2011. Detection of delta9-tetrahydrocannabinol in exhaled breath
collected from cannabis users. J Anal Toxicol;
35:541– 4.
About Cannabix
Technologies Inc.
Cannabix Technologies
Inc. is a leader in marijuana breathalyzer development for law
enforcement and the workplace. Cannabix has established breath
testing technologies in the pursuit of bringing accurate, durable,
portable tools to market to enable detection of marijuana-impaired
driving offences on roads at a time when marijuana is becoming
legal in many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in contrast to
urine testing for THC metabolite that requires an invasive
collection and reflects usage, days or even weeks earlier. The
devices will also be useful for other practical applications such
as testing employees in the workplace where impairment by THC can
be hazardous.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix Technologies
Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.